Research programme: acne therapeutics - Praxis

Drug Profile

Research programme: acne therapeutics - Praxis

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Praxis Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 15 Sep 2000 Findings of an initial clinical trial have been added to the adverse events and Skin Disorders pharmacodynamics section
  • 15 Sep 2000 Praxis Pharmaceuticals has filed a provisional patent for the anti-acne compound, which will give them worldwide priority for the compound
  • 23 Mar 2000 Phase-I clinical trials for Acne in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top